Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026

Arrowhead Pharmaceuticals (ARWR)

Nasdaq Health Care Biotechnology S&P MidCap 400
$58.16
+0.70 (+1.22%)
Close of Nov 06, 2026 · end-of-day data
Source: Arrowhead Pharmaceuticals's 10-K / 10-Q XBRL data on SEC EDGAR · fetched Nov 04, 2026

Revenue, net income & free cash flow

Income statement

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue$158.33K$31.41M$16.14M$168.80M$87.99M$138.29M$243.23M$240.74M$3.55M$829.45M
Research & development$62.12M$50.90M$52.97M$81.05M$128.88M$206.34M$297.31M$353.19M$505.87M$607.16M
Operating income-$81.74M-$37.00M-$55.94M$61.19M-$93.16M-$149.04M-$178.51M-$205.00M-$601.08M$98.35M
Interest expense—————$0$0$18.33M$32.35M$89.36M
Pre-tax income-$81.72M-$34.38M-$54.45M$68.15M-$84.55M-$140.85M-$172.71M-$206.49M-$612.46M$51.53M
Income tax$2.40K$2.40K$2.40K$174.00K$2.00K$2.00K$3.79M$2.78M-$2.77M$21.42M
Net income-$81.72M-$34.38M-$54.45M$67.97M-$84.55M-$140.85M-$176.06M-$205.28M-$599.49M-$1.63M
EBITDA-$78.48M-$34.01M-$52.94M$63.89M-$88.96M-$142.44M-$169.81M-$194.30M-$584.18M$120.55M
EPS (basic)$-1.34$-0.47$-0.65$0.72$-0.84$-1.36$-1.67$-1.92$-5.00$-0.01
EPS (diluted)$-1.34$-0.47$-0.65$0.69$-0.84$-1.36$-1.67$-1.92$-5.00$-0.01
Diluted shares61.05M73.90M83.64M98.61M100.72M103.75M105.43M106.75M119.78M133.76M
Operating margin-51627.1%-117.8%-346.5%36.3%-105.9%-107.8%-73.4%-85.2%-16927.1%11.9%
Net margin-51614.6%-109.5%-337.3%40.3%-96.1%-101.9%-72.4%-85.3%-16882.4%-0.2%

Balance sheet

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$85.37M$24.84M$30.13M$221.80M$143.58M$184.43M$108.00M$110.89M$102.69M$226.55M
Short-term investments————$85.02M$126.73M$0$292.74M$578.28M$692.82M
Receivables$75.00K$67.80K$327.38K$661.36K$846.00K$10.26M$1.41M$0$0$6.82M
Total current assets$90.50M$67.90M$78.77M$265.25M$322.37M$384.60M$405.30M$416.47M$695.47M$950.64M
Total assets$128.18M$104.02M$111.61M$349.85M$522.50M$710.15M$691.94M$765.55M$1.14B$1.39B
Total current liabilities$25.64M$18.70M$12.36M$97.07M$40.68M$146.54M$138.85M$105.46M$103.17M$195.49M
Total liabilities$32.60M$22.60M$15.81M$105.25M$60.72M$301.33M$293.42M$494.21M$954.36M$919.24M
Shareholders' equity$95.58M$81.42M$95.80M$244.59M$461.78M$408.82M$398.52M$271.34M$185.44M$466.05M

Cash flow

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-$64.43M-$23.94M-$47.22M$173.03M-$95.80M$171.31M-$136.13M-$153.89M-$462.85M$179.55M
Capital expenditures$3.86M$7.92M$1.42M$12.00M$11.95M$23.57M$52.78M$176.74M$141.47M$22.67M
Free cash flow-$68.29M-$31.86M-$48.64M$161.03M-$107.75M$147.75M-$188.91M-$330.63M-$604.32M$156.89M
Investing cash flow$13.45M-$48.64M-$7.43M-$47.75M-$240.78M-$141.68M-$5.42M-$96.16M-$420.07M-$129.29M
Financing cash flow$55.13M$12.06M$59.95M$66.38M$257.95M$11.30M$65.19M$253.05M$870.52M$74.01M
Stock-based compensation$11.60M$7.89M$8.45M$12.39M$43.38M$76.67M$120.89M$78.13M$73.97M$63.37M
Depreciation & amortization$3.26M$2.99M$3.00M$2.70M$4.20M$6.60M$8.70M$10.70M$16.90M$22.20M

Quarterly figures are rebuilt from the year-to-date totals companies report — Q4 is the full year minus the first nine months, since no 10-Q is filed for it. Values are as filed; later restatements replace earlier ones. Fiscal years are labelled by the calendar year in which they end.